We also recently developed a PSMA-targeted MNP and demonstrated the feasibility of preferentially targeting PSMA(+) tumors compared to PSMA(-) tumors at low and high MNP concentrations in preclinical PC models with high vascular permeability 51, 52. This evidence concerns the gene FOLH1 and pachyonychia congenita.